The cell-based gene therapy Breyanzi (lisocabtagene maraleucel) has received a positive opinion from the European Medicines Agency to treat patients with relapsed or refractory large B-cell lymphoma. Breyanzi was approved for the same indication in the US in 2021. It will be available to patients in the EU once the European Commission issues a marketing authorisation.
